|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||
  AddictionVolume 102 Issue 8, Pages 1292 - 1302 Published Online: 6 Jul 2007 Journal compilation © 2010 Society for the Study of Addiction Published on behalf of the Society for the Study of Addiction
Abstract | References | Full Text: HTML, PDF (Size: 221K) | Related Articles | Citation Tracking  RESEARCH REPORT A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse Copyright © 2007 The Authors. Journal compilation © 2007 Society for the Study of Addiction KEYWORDS Bupropion • maintenance treatment • nicotine gum • smoking cessation • smoking relapse ABSTRACTAim To investigate the efficacy of maintenance treatment with bupropion and/or nicotine gum for reducing smoking relapse. Design, setting and participants A 48-week study was conducted at a university-based smoking cessation clinic between February 2001 and October 2005. A total of 588 smokers received bupropion and nicotine patch in 8 weeks of open-label treatment (OLT); 289 abstainers during the last 4 weeks of OLT were randomized in double-blind placebo-controlled fashion to one of four arms for 16 weeks of maintenance treatment (MT) followed by 24 weeks of non-treatment follow-up (NTFU). Intervention Bupropion (300 mg/day) and 2 mg nicotine gum, used alone or combined, and comparable placebo pill and placebo gum. Behavioral counseling at all visits. Outcome Time to relapse (TTR) from randomization. Relapse is defined as the first 7 consecutive days of smoking. Abstinence verified by carbon monoxide ≤ 8 parts per million. Findings TTR was longer with extended active treatments compared to placebo (median days to relapse: bupropion + placebo = 136, nicotine + placebo = 98, bupropion + nicotine = 90, double placebo = 71). Hazard ratios (HR) for relapse were statistically significant for bupropion + placebo versus double placebo during MT (HR = 0.59, 95% CI = 0.37–0.92) and to the end of NTFU (HR = 0.66, 95% CI = 0.42–0.96). However, bupropion's advantage dissipated upon stopping the drug. Gum use was low, preventing a valid assessment; but analysis restricted to gum users suggested a weak effect of extended nicotine gum. Conclusion Maintenance treatment with bupropion exerted a modest benefit for preventing smoking relapse; the optimum duration of bupropion treatment was unclear. Further research is needed to ascertain the merits of extended use of nicotine gum, other nicotine replacement agents and other treatments known to aid smokers for preventing relapse once abstinence is achieved. Submitted 31 July 2006; initial review completed 27 November 2006; final version accepted 19 March 2007 | 
|
